Atea Pharmaceuticals, Inc. — Operating Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/e71d5b9b-21cf-41a9-9b31-db2638cbccbe/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-180.9M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-094159 |
| FY 2024 | $-192.9M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-034808 |
| FY 2023 | $-164.2M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-022226 |
| FY 2022 | $-130.7M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-005186 |
| FY 2021 | $138.4M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-007672 |
| FY 2020 | $-11.0M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-016724 |
| FY 2019 | $-14.6M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-016724 |
| FY 2018 | $-9.5M | 2018-01-01 – 2018-12-31 | evidence 0001564590-21-016724 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).